Development of neo-self antibody research for recurrent pregnancy loss and obstetric complications

Development of neo-self antibody research for recurrent pregnancy loss and obstetric complications - Development of neo-self antibody research for recurrent pregnancy loss and obstetric complications

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037771

Enrollment

1200

Registered

2019-08-22

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent pregnancy loss, obstetric complications, sterility

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Recurrent pregnancy loss 2) FGR 3) HDP 4) Preterm delivery 5) Sterility 6) Normal delivery without 1)-4) 7) Autoimmune disease obtaining written informed consent in 1)-7)

Exclusion criteria

Exclusion criteria: 1) Less than 18 years, or more than 45 years old 2) Inappropriate subjects 3) Multiple pregnancy or pregnancy with fetal anomaly

Design outcomes

Primary

Measure	Time frame
A caste-control study evaluate whether beta2GPI/HLA-DR7 antibody is associated with recurrent pregnancy loss, obstetric complications, or sterility	—

Secondary

Measure	Time frame
A cohort study for pregnant women (<21GW) evaluate whether beta2GPI/HLA-DR7 antibody is associated with obstetric complications	—

Countries

Japan

Contacts

Public ContactKenji Tanimura

Kobe University Graduate School of Medicine Department of Obstetrics & Gynecology

taniken@med.kobe-u.ac.jp0783826000

Outcome results